Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...
Image courtesy of the U.S. Centers for Disease Control. Over the past 50 years, survival rates for a group of blood cancers known as myelodysplastic syndrome (MDS) have not improved, despite the ...
The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS). However, most of what scientists know about the impact of ...
Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...
Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback